In addition, L-FABP significantly induces VEGF-A upregulation and increases angiogenic potential and migration activity in HCC cells by activating VEGF receptor-2 on membrane rafts and subsequently activating the Akt/mTOR/P70S6K/4EBP1 and Src/FAK/cdc42 pathways, suggesting that L-FABP may be a potential therapeutic target in HCC therapy [21, 42]. This evidence concerns the gene FABP1 and hepatocellular carcinoma.